Magnesium L-ThreonatevsNicotine

The L-threonate carrier forms stable complexes with magnesium and transports it across the blood-brain barrier via specific transporters more effectively than inorganic magnesium salts or other chelated forms. Once in the brain, magnesium acts as a voltage-dependent blocker of the NMDA receptor channel at the physiological magnesium binding site within the ion pore, preventing excessive calcium influx and glutamate-mediated excitotoxicity. Magnesium also serves as a cofactor for over 300 enzymes including those involved in neurotransmitter synthesis (tyrosine hydroxylase, glutamic acid decarboxylase), ATP production (creatine kinase, pyruvate kinase), and DNA/RNA polymerase. Elevated brain magnesium enhances synaptic density and plasticity in the hippocampus and prefrontal cortex, likely through CREB-mediated gene expression and increased density of postsynaptic AMPA receptors.

Nicotine binds to nicotinic acetylcholine receptors (nAChRs), particularly the high-affinity alpha-4-beta-2 subtype predominant in the brain, causing conformational changes that open the cation channel and allow Na+ and Ca2+ influx, depolarizing the neuron. This triggers vesicular release of dopamine (VTA to nucleus accumbens and prefrontal cortex), norepinephrine (locus coeruleus), acetylcholine (basal forebrain), serotonin, and glutamate. Cognitive enhancement comes from increased acetylcholine in the prefrontal cortex and hippocampus (attention, working memory) and dopamine in mesocortical pathways (motivation, executive function). Nicotine upregulates BDNF through nAChR-mediated Ca2+ signaling and CREB activation, and has anti-inflammatory effects via microglial alpha-7 nAChRs. Neuroprotection may involve reduced excitotoxicity and enhanced neuronal survival pathways.